SG11201401100UA - Antigen-binding molecule inducing immune response to target antigen - Google Patents
Antigen-binding molecule inducing immune response to target antigenInfo
- Publication number
- SG11201401100UA SG11201401100UA SG11201401100UA SG11201401100UA SG11201401100UA SG 11201401100U A SG11201401100U A SG 11201401100UA SG 11201401100U A SG11201401100U A SG 11201401100UA SG 11201401100U A SG11201401100U A SG 11201401100UA SG 11201401100U A SG11201401100U A SG 11201401100UA
- Authority
- SG
- Singapore
- Prior art keywords
- antigen
- immune response
- binding molecule
- inducing immune
- molecule inducing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011216958 | 2011-09-30 | ||
PCT/JP2012/075043 WO2013047729A1 (en) | 2011-09-30 | 2012-09-28 | Antigen-binding molecule inducing immune response to target antigen |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201401100UA true SG11201401100UA (en) | 2014-07-30 |
Family
ID=47995754
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201401100UA SG11201401100UA (en) | 2011-09-30 | 2012-09-28 | Antigen-binding molecule inducing immune response to target antigen |
SG10201510341XA SG10201510341XA (en) | 2011-09-30 | 2012-09-28 | Antigen-binding molecule inducing immune response to target antigen |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201510341XA SG10201510341XA (en) | 2011-09-30 | 2012-09-28 | Antigen-binding molecule inducing immune response to target antigen |
Country Status (14)
Country | Link |
---|---|
US (2) | US10556949B2 (en) |
EP (1) | EP2752200B1 (en) |
JP (3) | JP6352634B2 (en) |
KR (3) | KR102366029B1 (en) |
CN (4) | CN110680920A (en) |
AU (1) | AU2012317395B2 (en) |
BR (1) | BR112014007484A2 (en) |
CA (1) | CA2850322C (en) |
HK (1) | HK1198813A1 (en) |
MX (2) | MX366968B (en) |
RU (1) | RU2722829C9 (en) |
SG (2) | SG11201401100UA (en) |
TW (2) | TW201945034A (en) |
WO (1) | WO2013047729A1 (en) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2006381T3 (en) | 2006-03-31 | 2016-02-22 | Chugai Pharmaceutical Co Ltd | PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS |
HUE029635T2 (en) | 2007-09-26 | 2017-03-28 | Chugai Pharmaceutical Co Ltd | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
DK2708559T3 (en) | 2008-04-11 | 2018-06-14 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of repeatedly binding two or more antigen molecules |
TWI812066B (en) | 2010-11-30 | 2023-08-11 | 日商中外製藥股份有限公司 | Antibody having calcium-dependent antigen-binding ability |
KR20230005405A (en) | 2011-02-25 | 2023-01-09 | 추가이 세이야쿠 가부시키가이샤 | FcγRIIb-specific Fc antibody |
CA2839539C (en) | 2011-06-30 | 2021-06-08 | Chugai Seiyaku Kabushiki Kaisha | Heterodimerized polypeptide |
EP3939996A1 (en) | 2011-09-30 | 2022-01-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
CN110680920A (en) | 2011-09-30 | 2020-01-14 | 中外制药株式会社 | Antigen binding molecules that induce an immune response against a target antigen |
TW201817744A (en) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance |
CN108866101A (en) | 2011-10-28 | 2018-11-23 | 瑞泽恩制药公司 | Humanization IL-6 and IL-6 receptor |
KR20140100532A (en) | 2011-11-30 | 2014-08-14 | 추가이 세이야쿠 가부시키가이샤 | Drug containing carrier into cell for forming immune complex |
CA2865158C (en) * | 2012-02-24 | 2022-11-01 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib |
TWI797443B (en) | 2012-05-30 | 2023-04-01 | 日商中外製藥股份有限公司 | Screening or production method of antigen-binding molecule |
EP3721900A1 (en) | 2012-08-24 | 2020-10-14 | Chugai Seiyaku Kabushiki Kaisha | Fcgammariib-specific fc region variant |
EP2896291B1 (en) * | 2012-09-13 | 2019-03-20 | Chugai Seiyaku Kabushiki Kaisha | Gene knock-in non-human animal |
CN105102618B (en) | 2012-12-27 | 2018-04-17 | 中外制药株式会社 | heterodimerization polypeptide |
GB201302878D0 (en) * | 2013-02-19 | 2013-04-03 | Argen X Bv | Modified igG molecules |
TWI636062B (en) | 2013-04-02 | 2018-09-21 | 中外製藥股份有限公司 | Fc region variant |
JP7060317B2 (en) | 2013-12-04 | 2022-04-26 | 中外製薬株式会社 | Antigen-binding molecule and its library whose antigen-binding ability changes according to the concentration of the compound |
TWI779010B (en) | 2014-12-19 | 2022-10-01 | 日商中外製藥股份有限公司 | ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT Fc REGIONs, AND METHODS OF USE |
EP3253778A1 (en) | 2015-02-05 | 2017-12-13 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
EP4353750A3 (en) * | 2016-06-24 | 2024-07-24 | iCell Gene Therapeutics LLC | Chimeric antigen receptors (cars), compositions and methods thereof |
EP3481864A1 (en) | 2016-07-08 | 2019-05-15 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
AU2017325654B2 (en) | 2016-08-02 | 2024-09-05 | Visterra, Inc. | Engineered polypeptides and uses thereof |
KR102538749B1 (en) | 2016-08-05 | 2023-06-01 | 추가이 세이야쿠 가부시키가이샤 | Composition for prophylaxis or treatment of il-8 related diseases |
SG11201900746RA (en) * | 2016-08-12 | 2019-02-27 | Janssen Biotech Inc | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions |
MA50958A (en) | 2017-04-21 | 2020-10-14 | Staten Biotechnology B V | ANTI-APOC3 ANTIBODIES AND THEIR METHODS OF USE |
US10538583B2 (en) | 2017-10-31 | 2020-01-21 | Staten Biotechnology B.V. | Anti-APOC3 antibodies and compositions thereof |
CN111315772A (en) | 2017-10-31 | 2020-06-19 | 斯塔顿生物技术有限公司 | anti-APOC 3 antibodies and methods of use thereof |
WO2019098212A1 (en) | 2017-11-14 | 2019-05-23 | Chugai Seiyaku Kabushiki Kaisha | Anti-c1s antibodies and methods of use |
US20210324099A1 (en) * | 2018-08-10 | 2021-10-21 | Chugai Seiyaku Kabushiki Kaisha | Anti-cd137 antigen-binding molecule and utilization thereof |
EP3883964A1 (en) | 2018-11-20 | 2021-09-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Bispecific antibody targeting transferrin receptor 1 and soluble antigen |
EP3974446A4 (en) * | 2019-05-23 | 2023-08-02 | Xiamen University | Anti-hepatitis b virus antibodies and use thereof |
EP4086281A4 (en) * | 2019-12-30 | 2024-02-14 | China Immunotech (Beijing) Biotechnology Co., Ltd | Enhanced t-cell receptor star and application thereof |
CN112779224A (en) * | 2021-01-27 | 2021-05-11 | 河南省华隆生物技术有限公司 | NK trophoblast cell expressing cytokine composition and preparation method and application thereof |
CN112725273A (en) * | 2021-01-27 | 2021-04-30 | 河南省华隆生物技术有限公司 | NK cell and preparation method and application thereof |
CN112725284A (en) * | 2021-01-27 | 2021-04-30 | 河南省华隆生物技术有限公司 | NK trophoblast cell and application thereof |
CN112852744A (en) * | 2021-01-27 | 2021-05-28 | 河南省华隆生物技术有限公司 | NK trophoblast cell and preparation method and application thereof |
CA3209059A1 (en) * | 2021-02-25 | 2022-09-01 | Leslie W. Tari | Variant fc domains and uses thereof |
CN113332417A (en) * | 2021-04-27 | 2021-09-03 | 大汉生物科技(广东)有限公司 | Application of TREM-2 in preparation of tumor treatment medicine and/or diagnostic reagent |
CN114921436B (en) * | 2022-03-03 | 2023-08-04 | 翌圣生物科技(上海)股份有限公司 | Terminal deoxynucleotidyl transferase mutant, encoding gene, recombinant expression plasmid and genetically engineered bacterium thereof |
CN114716547B (en) * | 2022-05-18 | 2023-11-21 | 珠海丽禾医疗诊断产品有限公司 | Binding proteins comprising antigen binding domains and methods of production and use thereof |
CN115028685B (en) * | 2022-06-24 | 2023-10-20 | 张金强 | Cationic bicyclic antibacterial peptide and application thereof |
CN115353566B (en) * | 2022-09-14 | 2023-05-09 | 江苏睿源生物技术有限公司 | Antibody combination for detecting interleukin 1-beta and application thereof |
Family Cites Families (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
JPH06508511A (en) | 1990-07-10 | 1994-09-29 | ケンブリッジ アンティボディー テクノロジー リミティド | Method for producing specific binding pair members |
DK0814159T3 (en) | 1990-08-29 | 2005-10-24 | Genpharm Int | Transgenic, non-human animals capable of forming heterologous antibodies |
DE69229477T2 (en) | 1991-09-23 | 1999-12-09 | Cambridge Antibody Technology Ltd., Melbourn | Methods for the production of humanized antibodies |
ES2313867T3 (en) | 1991-12-02 | 2009-03-16 | Medical Research Council | ANTI-AUTO ANTIBODY PRODUCTION OF ANTIBODY SEGMENT REPERTORIES EXPRESSED ON THE PAYMENT SURFACE. |
CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
WO1993019172A1 (en) | 1992-03-24 | 1993-09-30 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
CA2140638C (en) | 1992-07-24 | 2010-05-04 | Raju Kucherlapati | Generation of xenogeneic antibodies |
US5648267A (en) | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
FR2707189B1 (en) | 1993-07-09 | 1995-10-13 | Gradient Ass | Method for treating combustion residues and installation for implementing said method. |
EP0731842A1 (en) | 1993-12-03 | 1996-09-18 | Medical Research Council | Recombinant binding proteins and peptides |
AU701342B2 (en) | 1994-07-13 | 1999-01-28 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin-8 |
EP1709970A1 (en) | 1995-04-27 | 2006-10-11 | Abgenix, Inc. | Human antibodies against EGFR, derived from immunized xenomice |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6277375B1 (en) * | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
AU3657899A (en) * | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
KR101155191B1 (en) | 1999-01-15 | 2012-06-13 | 제넨테크, 인크. | Polypeptide Variants with Altered Effector Function |
US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
ES2571230T3 (en) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedure to control the activity of an immunofunctional molecule |
WO2002020565A2 (en) | 2000-09-08 | 2002-03-14 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
EA013224B1 (en) | 2000-10-06 | 2010-04-30 | Киова Хакко Кирин Ко., Лтд. | Cells producing antibody compositions |
AU2002213251B2 (en) | 2000-10-16 | 2007-06-14 | Bristol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
US7658921B2 (en) * | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
DE60143544D1 (en) | 2000-12-12 | 2011-01-05 | Medimmune Llc | MOLECULES WITH LONGER MID-TERM, COMPOSITIONS AND THEIR USE |
US20030003097A1 (en) | 2001-04-02 | 2003-01-02 | Idec Pharmaceutical Corporation | Recombinant antibodies coexpressed with GnTIII |
US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
PT1411118E (en) | 2001-06-22 | 2008-12-09 | Chugai Pharmaceutical Co Ltd | Cell proliferation inhibitors containing anti-glypican-3 antibody |
WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
BRPI0214168B8 (en) * | 2001-11-14 | 2021-05-25 | Centocor Inc | anti-il-6 antibodies, nucleic acid molecules encoding the same, vectors comprising said molecules, compositions and formulations comprising said antibodies, as well as methods of producing the same |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
AU2003242024A1 (en) | 2002-06-05 | 2003-12-22 | Chugai Seiyaku Kabushiki Kaisha | Method of constructing antibody |
AU2003256266A1 (en) | 2002-06-12 | 2003-12-31 | Genencor International, Inc. | Methods and compositions for milieu-dependent binding of a targeted agent to a target |
CN100347994C (en) * | 2002-06-21 | 2007-11-07 | 汤姆森特许公司 | Linearly expandable broadcast router apparatus |
WO2004022595A1 (en) | 2002-09-04 | 2004-03-18 | Chugai Seiyaku Kabushiki Kaisha | CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE |
EP2364996B1 (en) | 2002-09-27 | 2016-11-09 | Xencor Inc. | Optimized FC variants and methods for their generation |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US20090010920A1 (en) * | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
AU2004284090A1 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | LDL receptor class A and EGF domain monomers and multimers |
WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
WO2005070963A1 (en) | 2004-01-12 | 2005-08-04 | Applied Molecular Evolution, Inc | Fc region variants |
US20050260711A1 (en) | 2004-03-30 | 2005-11-24 | Deepshikha Datta | Modulating pH-sensitive binding using non-natural amino acids |
CN1997667A (en) * | 2004-05-10 | 2007-07-11 | 宏观基因有限公司 | Humanized FcgammaRIIB-specific antibodies and methods of use thereof |
NZ579543A (en) | 2004-07-09 | 2011-07-29 | Chugai Pharmaceutical Co Ltd | Anti-glypican 3 antibody |
SI2471813T1 (en) * | 2004-07-15 | 2015-03-31 | Xencor, Inc. | Optimized Fc variants |
EP2213683B1 (en) | 2004-08-04 | 2013-06-05 | Mentrik Biotech, LLC | Variant Fc regions |
US7659374B2 (en) | 2004-08-16 | 2010-02-09 | Medimmune, Llc | Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity |
KR20070057839A (en) * | 2004-08-19 | 2007-06-07 | 제넨테크, 인크. | Polypeptide variants with altered effector function |
CA2587766A1 (en) | 2004-11-10 | 2007-03-01 | Macrogenics, Inc. | Engineering fc antibody regions to confer effector function |
AU2005304624B2 (en) * | 2004-11-12 | 2010-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US20090061485A1 (en) | 2004-12-22 | 2009-03-05 | Chugai Seiyaku Kabushiki Kaisha | Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited |
AU2006230413B8 (en) | 2005-03-31 | 2011-01-20 | Xencor, Inc | Fc variants with optimized properties |
EP1870459B1 (en) * | 2005-03-31 | 2016-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
US8008443B2 (en) | 2005-04-26 | 2011-08-30 | Medimmune, Llc | Modulation of antibody effector function by hinge domain engineering |
BRPI0611445A2 (en) * | 2005-05-09 | 2010-09-08 | Glycart Biotechnology Ag | glycomanipulated antigen binding molecule, polynucleotide, polypeptide, vector, host cell, method for production, use and pharmaceutical composition |
US8191469B2 (en) | 2005-05-27 | 2012-06-05 | The Glad Products Company | Device and method for evacuating a storage bag |
US8163881B2 (en) * | 2005-05-31 | 2012-04-24 | The Board Of Regents Of The University Of Texas System | Immunoglobulin molecules with improved characteristics |
WO2007021841A2 (en) | 2005-08-10 | 2007-02-22 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
KR101379568B1 (en) * | 2005-08-26 | 2014-04-08 | 로슈 글리카트 아게 | Modified antigen binding molecules with altered cell signaling activity |
DK1931709T3 (en) | 2005-10-03 | 2017-03-13 | Xencor Inc | FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES |
AU2007281284A1 (en) | 2006-08-02 | 2008-02-07 | The Uab Research Foundation | Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity |
US20100034194A1 (en) * | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
AU2008203703C1 (en) | 2007-01-05 | 2014-04-03 | University Of Zurich | Method of providing disease-specific binding molecules and targets |
CN101679966B (en) * | 2007-01-24 | 2014-03-12 | 协和发酵麒麟株式会社 | Genetically recombinant antibody composition having enhanced effector activity |
WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
EP4269443A3 (en) | 2007-12-26 | 2023-12-27 | Xencor, Inc. | Fc variants with altered binding to fcrn |
DK2708559T3 (en) * | 2008-04-11 | 2018-06-14 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of repeatedly binding two or more antigen molecules |
JP2011519279A (en) | 2008-05-01 | 2011-07-07 | アムジエン・インコーポレーテツド | Anti-hepcidin antibodies and methods of use |
PE20110707A1 (en) * | 2008-10-14 | 2011-10-11 | Genentech Inc | IMMUNOGLOBULIN VARIANTS |
JP5807300B2 (en) * | 2008-11-18 | 2015-11-10 | 株式会社シノテスト | Method and reagent for measuring C-reactive protein in sample |
JP2012515556A (en) | 2009-01-23 | 2012-07-12 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Stabilized Fc polypeptides with reduced effector function and methods of use |
WO2010088444A1 (en) * | 2009-01-29 | 2010-08-05 | Medimmune, Llc | Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases |
EP2233500A1 (en) | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
DK2435568T3 (en) | 2009-05-29 | 2014-09-08 | Morphosys Ag | Collection of synthetic antibodies to treat disease |
WO2011008517A2 (en) * | 2009-06-30 | 2011-01-20 | Research Development Foundation | Immunoglobulin fc polypeptides |
US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
KR20120138241A (en) | 2010-03-11 | 2012-12-24 | 화이자 인코포레이티드 | Antibodies with ph dependent antigen binding |
TWI667257B (en) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | Antibodies with modified affinity to fcrn that promote antigen clearance |
TWI812066B (en) * | 2010-11-30 | 2023-08-11 | 日商中外製藥股份有限公司 | Antibody having calcium-dependent antigen-binding ability |
KR20230005405A (en) * | 2011-02-25 | 2023-01-09 | 추가이 세이야쿠 가부시키가이샤 | FcγRIIb-specific Fc antibody |
EP3939996A1 (en) * | 2011-09-30 | 2022-01-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
WO2013047752A1 (en) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | Antigen-binding molecule for promoting loss of antigens |
CN110680920A (en) | 2011-09-30 | 2020-01-14 | 中外制药株式会社 | Antigen binding molecules that induce an immune response against a target antigen |
TW201817744A (en) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance |
SG11201401102VA (en) | 2011-09-30 | 2014-09-26 | Chugai Pharmaceutical Co Ltd | Ion concentration-dependent binding molecule library |
KR20140100532A (en) | 2011-11-30 | 2014-08-14 | 추가이 세이야쿠 가부시키가이샤 | Drug containing carrier into cell for forming immune complex |
TWI797443B (en) | 2012-05-30 | 2023-04-01 | 日商中外製藥股份有限公司 | Screening or production method of antigen-binding molecule |
ES2856272T3 (en) | 2012-05-30 | 2021-09-27 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule to remove aggregated antigens |
CA2925256C (en) * | 2013-09-27 | 2023-08-15 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
AU2015283270B9 (en) | 2014-06-30 | 2021-04-01 | Merck Patent Gmbh | Anti-TNFa antibodies with pH-dependent antigen binding |
TWI779010B (en) | 2014-12-19 | 2022-10-01 | 日商中外製藥股份有限公司 | ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT Fc REGIONs, AND METHODS OF USE |
PL3233921T3 (en) | 2014-12-19 | 2022-01-10 | Chugai Seiyaku Kabushiki Kaisha | Anti-c5 antibodies and methods of use |
EP3253778A1 (en) | 2015-02-05 | 2017-12-13 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
EP3279216A4 (en) * | 2015-04-01 | 2019-06-19 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide hetero-oligomer |
-
2012
- 2012-09-28 CN CN201910948771.6A patent/CN110680920A/en active Pending
- 2012-09-28 WO PCT/JP2012/075043 patent/WO2013047729A1/en active Application Filing
- 2012-09-28 AU AU2012317395A patent/AU2012317395B2/en active Active
- 2012-09-28 US US14/347,448 patent/US10556949B2/en active Active
- 2012-09-28 MX MX2014003832A patent/MX366968B/en active IP Right Grant
- 2012-09-28 KR KR1020217007933A patent/KR102366029B1/en active IP Right Grant
- 2012-09-28 KR KR1020227005032A patent/KR102492584B1/en active IP Right Grant
- 2012-09-28 CN CN201280058767.9A patent/CN104093424A/en active Pending
- 2012-09-28 SG SG11201401100UA patent/SG11201401100UA/en unknown
- 2012-09-28 CA CA2850322A patent/CA2850322C/en active Active
- 2012-09-28 EP EP12836146.6A patent/EP2752200B1/en active Active
- 2012-09-28 KR KR1020147011134A patent/KR102239138B1/en active IP Right Grant
- 2012-09-28 TW TW108133038A patent/TW201945034A/en unknown
- 2012-09-28 TW TW101135762A patent/TWI681970B/en active
- 2012-09-28 CN CN201910951675.7A patent/CN110655578A/en active Pending
- 2012-09-28 JP JP2013536417A patent/JP6352634B2/en active Active
- 2012-09-28 CN CN201910947171.8A patent/CN110627902A/en active Pending
- 2012-09-28 RU RU2014117504A patent/RU2722829C9/en active
- 2012-09-28 SG SG10201510341XA patent/SG10201510341XA/en unknown
- 2012-09-28 BR BR112014007484A patent/BR112014007484A2/en not_active Application Discontinuation
-
2014
- 2014-03-28 MX MX2019006188A patent/MX2019006188A/en unknown
- 2014-12-08 HK HK14112300.4A patent/HK1198813A1/en unknown
-
2018
- 2018-06-07 JP JP2018109098A patent/JP7029355B2/en active Active
-
2019
- 2019-12-17 US US16/717,064 patent/US20200115447A1/en active Pending
-
2021
- 2021-10-04 JP JP2021163532A patent/JP2022000472A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1198813A1 (en) | Antigen-binding molecule inducing immune response to target antigen | |
IL276234B (en) | Antibody formulations | |
HRP20181690T1 (en) | Antibody fc variants | |
HK1198578A1 (en) | Antigen-binding molecule for promoting elimination of antigens | |
IL229254A0 (en) | Therapeutic antibodies | |
CO7020871A2 (en) | Anti-il-36r antibodies | |
ZA201400768B (en) | Interleukin-31 monoclonal antibody | |
IL228001A0 (en) | Antibodies to cd70 | |
DK3275892T3 (en) | PRÆFUSIONS-RSV F ANTIGENS | |
GB201103955D0 (en) | Antibodies | |
GB201112056D0 (en) | Antibodies | |
IL227796A0 (en) | Methods for enhancing immunogen specific immune respones by vectored vaccines | |
CO6841994A2 (en) | Antibodies | |
EP2714074A4 (en) | Anti-emr1 antibodies | |
ZA201308992B (en) | Therapeutic antibodies |